Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inclusion Body Myositis (IBM) Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers

NCT00805870
View directory record Official record
Conditions
Muscle Damage, Muscle Inflammation
Interventions
Lovaza (omega-3-acid ethyl esters), Wheat Germ Oil
Drug
Lead sponsor
Western Michigan University
Other
Eligibility
18 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 1, 2026, 4:47 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Adult and Juvenile Myositis

NCT00017914
View directory record Official record
Conditions
Dermatomyositis, Polymyositis, Inclusion Body Myositis
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
2 Years to 100 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1995
U.S. locations
4
States / cities
Atlanta, Georgia • Bethesda, Maryland • Research Triangle Park, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 1, 2026, 4:47 PM EDT
Completed Early Phase 1 Interventional

Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis

NCT00802815
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
Etanercept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 1, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Efficacy of a New Delivery System for Beta-hydroxy-beta-methylbutyrate

NCT01150526
View directory record Official record
Conditions
Healthy
Interventions
CaHMB, HMB Free Acid Gel, Placebo, Placebo Gel Dosage
Dietary Supplement
Lead sponsor
Metabolic Technologies Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Oct 1, 2026, 4:47 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Influence of Aerobic Training and Weight Loss on Skeletal Muscle Inflammatory Markers and Muscle Protein Balance in Older Adults

NCT03743675
View directory record Official record
Conditions
Overweight and Obesity, Inflammation; Muscle, Sedentary Lifestyle
Interventions
Diet-Induced Weight Loss, Aerobic Exercise Training
Behavioral
Lead sponsor
Miami University
Other
Eligibility
58 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Oxford, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 1, 2026, 4:47 PM EDT
Recruiting Early Phase 1 Interventional

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

NCT06479863
View directory record Official record
Conditions
Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
Interventions
Pozelimab/Cemdisiran
Combination Product
Lead sponsor
Austin Neuromuscular Center
Other
Eligibility
45 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 1, 2026, 4:47 PM EDT
Completed Phase 1 Interventional

Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis

NCT01519349
View directory record Official record
Conditions
Becker Muscular Dystrophy, Sporadic Inclusion Body Myositis
Interventions
rAAV1.CMV.huFollistatin344
Biological
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 1, 2026, 4:47 PM EDT
Active, not recruiting No phase listed Observational

Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time

NCT06153108
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
PAMSys pendant PAMSys wrist sensors
Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
45 Years and older
Enrollment
20 participants
Timeline
2023 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 1, 2026, 4:47 PM EDT
Recruiting Not applicable Interventional

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

NCT07478172
View directory record Official record
Conditions
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis, Myasthenia Gravis, Lambert-eaton Myasthenic Syndrome, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Charcot Marie Tooth Disease (CMT), Fascioscapulohumeral Muscular Dystrophy, Inclusion Body Myositis, Mitochondrial Myopathy, Nemaline Myopathy, Centronuclear Myopathy, Postpolio Syndrome, Pompe Disease (Late-onset), Chronic Inflammatory Demyelinating Polyneuropathy, Hereditary Spastic Paraplegia, Postural Orthostatic Tachycardia Syndrome (POTS), Progressive Muscular Atrophy
Interventions
Whole-body Electrical Muscle Stimulation Exercise
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 1, 2026, 4:47 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis

NCT06450886
View directory record Official record
Conditions
Inclusion Body Myositis (IBM)
Interventions
Ulviprubart (ABC008)
Drug
Lead sponsor
Abcuro, Inc.
Industry
Eligibility
40 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 1, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

NCT02573467
View directory record Official record
Conditions
Sporadic Inclusion Body Myositis
Interventions
Bimagrumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
36 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 1, 2026, 4:47 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

NCT01925209
View directory record Official record
Conditions
Sporadic Inclusion Body Myositis
Interventions
BYM338/bimagrumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
36 Years to 85 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 1, 2026, 4:47 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms

NCT01032993
View directory record Official record
Conditions
Pain, Weakness, Cramps, Myalgia or Myositis Nos, HMG COA Reductase Inhibitor Adverse Reaction
Interventions
Coenzyme Q10, Placebo
Dietary Supplement · Other
Lead sponsor
Catherine Buettner
Other
Eligibility
21 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 1, 2026, 4:47 PM EDT